Proteopathic tau seeding predicts tauopathy in vivo

Brandon B. Holmes, Jennifer L. Furman, Thomas E. Mahan, Tritia R. Yamasaki, Hilda Mirbaha, William C. Eades, Larisa Belaygorod, Nigel J. Cairns, David M. Holtzman, Marc I. Diamond

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer's disease, this model predicts that tau seeds propagate pathology through the brain via cell-cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (∼300 fM) and synuclein (∼300 pM) fibrils. This assay readily discriminates Alzheimer's disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, >1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.

Original languageEnglish (US)
Pages (from-to)E4376-E4385
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number41
DOIs
StatePublished - Oct 14 2014

Fingerprint

Tauopathies
Synucleins
Seeds
Pathology
Alzheimer Disease
Prions
Huntington Disease
Brain
Biosensing Techniques
Neurodegenerative Diseases
Flow Cytometry
Coloring Agents
Sensitivity and Specificity

Keywords

  • Aging
  • Amyloid
  • Dementia
  • Neuropathology

ASJC Scopus subject areas

  • General

Cite this

Proteopathic tau seeding predicts tauopathy in vivo. / Holmes, Brandon B.; Furman, Jennifer L.; Mahan, Thomas E.; Yamasaki, Tritia R.; Mirbaha, Hilda; Eades, William C.; Belaygorod, Larisa; Cairns, Nigel J.; Holtzman, David M.; Diamond, Marc I.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 41, 14.10.2014, p. E4376-E4385.

Research output: Contribution to journalArticle

Holmes, BB, Furman, JL, Mahan, TE, Yamasaki, TR, Mirbaha, H, Eades, WC, Belaygorod, L, Cairns, NJ, Holtzman, DM & Diamond, MI 2014, 'Proteopathic tau seeding predicts tauopathy in vivo', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 41, pp. E4376-E4385. https://doi.org/10.1073/pnas.1411649111
Holmes, Brandon B. ; Furman, Jennifer L. ; Mahan, Thomas E. ; Yamasaki, Tritia R. ; Mirbaha, Hilda ; Eades, William C. ; Belaygorod, Larisa ; Cairns, Nigel J. ; Holtzman, David M. ; Diamond, Marc I. / Proteopathic tau seeding predicts tauopathy in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 41. pp. E4376-E4385.
@article{e8c166384ca0445a9ad7012a12a0b418,
title = "Proteopathic tau seeding predicts tauopathy in vivo",
abstract = "Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer's disease, this model predicts that tau seeds propagate pathology through the brain via cell-cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (∼300 fM) and synuclein (∼300 pM) fibrils. This assay readily discriminates Alzheimer's disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, >1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.",
keywords = "Aging, Amyloid, Dementia, Neuropathology",
author = "Holmes, {Brandon B.} and Furman, {Jennifer L.} and Mahan, {Thomas E.} and Yamasaki, {Tritia R.} and Hilda Mirbaha and Eades, {William C.} and Larisa Belaygorod and Cairns, {Nigel J.} and Holtzman, {David M.} and Diamond, {Marc I.}",
year = "2014",
month = "10",
day = "14",
doi = "10.1073/pnas.1411649111",
language = "English (US)",
volume = "111",
pages = "E4376--E4385",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "41",

}

TY - JOUR

T1 - Proteopathic tau seeding predicts tauopathy in vivo

AU - Holmes, Brandon B.

AU - Furman, Jennifer L.

AU - Mahan, Thomas E.

AU - Yamasaki, Tritia R.

AU - Mirbaha, Hilda

AU - Eades, William C.

AU - Belaygorod, Larisa

AU - Cairns, Nigel J.

AU - Holtzman, David M.

AU - Diamond, Marc I.

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer's disease, this model predicts that tau seeds propagate pathology through the brain via cell-cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (∼300 fM) and synuclein (∼300 pM) fibrils. This assay readily discriminates Alzheimer's disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, >1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.

AB - Transcellular propagation of protein aggregates, or proteopathic seeds, may drive the progression of neurodegenerative diseases in a prion-like manner. In tauopathies such as Alzheimer's disease, this model predicts that tau seeds propagate pathology through the brain via cell-cell transfer in neural networks. The critical role of tau seeding activity is untested, however. It is unknown whether seeding anticipates and correlates with subsequent development of pathology as predicted for a causal agent. One major limitation has been the lack of a robust assay to measure proteopathic seeding activity in biological specimens. We engineered an ultrasensitive, specific, and facile FRET-based flow cytometry biosensor assay based on expression of tau or synuclein fusions to CFP and YFP, and confirmed its sensitivity and specificity to tau (∼300 fM) and synuclein (∼300 pM) fibrils. This assay readily discriminates Alzheimer's disease vs. Huntington's disease and aged control brains. We then carried out a detailed time-course study in P301S tauopathy mice, comparing seeding activity versus histological markers of tau pathology, including MC1, AT8, PG5, and Thioflavin S. We detected robust seeding activity at 1.5 mo, >1 mo before the earliest histopathological stain. Proteopathic tau seeding is thus an early and robust marker of tauopathy, suggesting a proximal role for tau seeds in neurodegeneration.

KW - Aging

KW - Amyloid

KW - Dementia

KW - Neuropathology

UR - http://www.scopus.com/inward/record.url?scp=84907894705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907894705&partnerID=8YFLogxK

U2 - 10.1073/pnas.1411649111

DO - 10.1073/pnas.1411649111

M3 - Article

VL - 111

SP - E4376-E4385

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 41

ER -